A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas

Cancer

Volumn 117, Issue 21, 2011, Pages 4905-4915

  Couldwell, William T ^a   Surnock, Amy A ^b   Tobia, Alfonso J ^c   Cabana, Bernard E ^c   Stillerman, Charles B ^d   Forsyth, Peter A ^e   Appley, Alan J ^f   Spence, Alexander M ^g   Hinton, David R ^b   Chen, Thomas C ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Hy BioPharma Inc   (United States)

^d Trinity Health Minot   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f Acadiana Neurosurgery   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

brain tumor; chemotherapy; glioma; hypericin; recurrent

Indexed keywords

HYPERICIN;

ABDOMINAL DISTENSION; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HUMAN; HYPERESTHESIA; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOTOXICITY; PRIORITY JOURNAL; SKIN BURNING SENSATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERYLENE;

EID: 80052889492     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26123     Document Type: Article

References (27)

1. Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A. 1989; 86: 5963-5967. (Pubitemid 19217568)
2. Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2001; 45: 517-524. (Pubitemid 32105289)
3. Couldwell WT, Antel JP, Yong VW,. Protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery. 1992; 31: 717-724; discussion 724.
4. Couldwell WT, Gopalakrishna R, Hinton DR, et al. Hypericin: a potential antiglioma therapy. Neurosurgery. 1994; 35: 705-709; discussion 709-710.
5. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G,. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003; 63: 8241-8247. (Pubitemid 37549474)
6. Fox FE, Niu Z, Tobia A, Rook AH,. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol. 1998; 111: 327-332. (Pubitemid 28354724)
7. Lavie G, Mandel M, Hazan S, et al. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis. 2005; 8: 35-42. (Pubitemid 41223837)
8. Alecu M, Ursaciuc C, Halalau F, et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res. 1998; 18: 4651-4654. (Pubitemid 29042039)
9. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B,. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010; 63: 984-990.
10. Kacerovska D, Pizinger K, Majer F, Smid F,. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract-a pilot study. Photochem Photobiol. 2008; 84: 779-785. (Pubitemid 351589362)
11. Liebes L, Mazur Y, Freeman D, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem. 1991; 195: 77-85.
12. National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual, version 2.0. Washington, DC: National Cancer Institute; 1999.
13. Couldwell WT, Antel JP, Apuzzo ML, Yong VW,. Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg. 1990; 73: 594-600. (Pubitemid 20319480)
14. Couldwell WT, Uhm JH, Antel JP, Yong VW,. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery. 1991; 29: 880-886; discussion 886-887.
15. Huang LE, Gu J, Schau M, Bunn HF,. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998; 95: 7987-7992.
16. Anker L, Gopalakrishna R, Law R, Jones K, Couldwell W,. Hypericin: an antitumor agent. Drugs Future. 1995; 20: 511-517.
17. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2006; 95: 1155-1160. (Pubitemid 44658477)
18. Brem H, Mahaley MS, Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991; 74: 441-446.
19. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
20. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65: 7462-7469. (Pubitemid 41161281)
21. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009; 15: 3617-3623.
22. Propper DJ, Macaulay V, O'Byrne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 1998; 78: 1337-1341. (Pubitemid 28495246)
23. Gupta V, Su YS, Wang W, et al. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin [serial online]. Neurosurg Focus. 2006; 20 (4): e20.
24. Zhang W, Anker L, Law RE, et al. Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Clin Cancer Res. 1996; 2: 843-846. (Pubitemid 26169990)
25. Chen TC, Su S, Fry D, Liebes L,. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer. 2003; 97: 2363-2373. (Pubitemid 36444047)
26. Hopfner M, Maaser K, Theiss A, et al. Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells. Int J Colorectal Dis. 2003; 18: 239-247. (Pubitemid 36764171)
27. Yee KK, Soo KC, Olivo M,. Anti-angiogenic effects of hypericin- photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int J Mol Med. 2005; 16: 993-1002.